Susquehanna International Group, LLP Acumen Pharmaceuticals, Inc. Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$2.22 - $3.54 $27,306 - $43,542	-12,300 Reduced 36.83%	21,100 $52,000
Q2 2024 Aug 15, 2024	SELL	$2.14 - $4.01 $92,662 - $173,633	-43,300 Reduced 56.45%	33,400 $80,000
Q1 2024 May 07, 2024	SELL	$2.97 - $4.64 $339,768 - $530,816	-114,400 Reduced 59.86%	76,700 $310,000
Q4 2023 Feb 14, 2024	SELL	$1.86 - $4.48 $7,254 - $17,472	-3,900 Reduced 2.0%	191,100 $733,000
Q3 2023 Nov 14, 2023	BUY	$4.15 - $9.72 $448,615 - $1.05 Million	108,100 Added 124.4%	195,000 $809,000
Q2 2023 Aug 11, 2023	BUY	$3.59 - $6.59 $132,830 - $243,830	37,000 Added 74.15%	86,900 $417,000
Q1 2023 May 16, 2023	BUY	$3.75 - $6.65 $126,000 - $223,440	33,600 Added 206.13%	49,900 $202,000
Q4 2022 Feb 14, 2023	BUY	$4.81 - $10.17 $25,011 - $52,884	5,200 Added 46.85%	16,300 $88,000
Q3 2022 Nov 14, 2022	BUY	$4.44 - $10.48 $4,440 - $10,480	1,000 Added 9.9%	11,100 $111,000

41.8M

57.7K

749K

Ticker ABOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,503,100
Market Cap $79.8M
Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Ph...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.